Laura Ayling

Director of Commercial Partnerships and Strategy

Laura has over 15 years’ experience across the pharmaceutical industry, from Research & Development through to commercial supply. Laura specialises in the end-to-end Due Diligence of in-licensing opportunities and acquisitions of products and portfolios across formulations and therapeutic areas with a focus on blood-related oncologies. She joined the organisation as Commercial Development & Alliance Manager to lead the onboarding of Clinigen, providing support across the business.

Over the next 3 years, her role steadily expanded to encompass supply and demand of Erwinase and Anthrax Vaccine, be the point of contact for all major third party relationships including the MoD, Baccinex, Almac and PCi, contract review, patent and trademarking, market access, Business Transformation, amongst other key responsibilities before transitioning into the current role in October 2022.

Laura graduated with a PhD from Cambridge University, Pharmacology Department after obtaining a first-class BSc in Medical Biochemistry. She has several peer-reviewed first author publications and has presented her original research at a number of conferences